Peanut Allergy Market is projected to reach USD 4.08 billion by 2034

The global Peanut Allergy Market was valued at USD 1.32 billion in 2024 and is projected to reach USD 4.08 billion by 2034, expanding at a strong CAGR of 11.9% from 2025 to 2034. Market growth is driven by rising prevalence of food allergies globally, increasing adoption of immunotherapy-based treatment approaches, and regulatory approvals of novel desensitization therapies for children and adolescents.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71354

Peanut allergy is one of the most common and severe food allergies, particularly in children, and is associated with life-threatening anaphylaxis. Traditional management has relied on strict avoidance and emergency epinephrine use. However, the market is undergoing a major shift with the commercialization of oral immunotherapy (OIT), development of epicutaneous immunotherapy (EPIT) patches, sublingual immunotherapy (SLIT), and advanced biologics targeting IgE-mediated hypersensitivity.

Key Market Highlights
• 2024 Market Size: USD 1.32 billion
• 2034 Forecast: USD 4.08 billion
• CAGR (2025-2034): 11.9%
• Largest Segment: Oral Immunotherapy (OIT)
• Fastest-Growing Segment: Biologic therapies

Epidemiology & Clinical Insights
1. Prevalence
• Peanut allergy affects ~1-2% of children in many Western countries.
• Prevalence increasing globally due to changing dietary patterns and early-life sensitization.
• Approximately 20% of children may outgrow the condition, but the majority remain allergic into adulthood.
2. Clinical Severity
Symptoms range from:
• Urticaria
• Angioedema
• Gastrointestinal distress
• Respiratory compromise
• Anaphylaxis (life-threatening)
3. Diagnosis
• Skin prick testing
• Peanut-specific IgE measurement
• Component-resolved diagnostics (Ara h2)
• Oral food challenge (gold standard)
Market Growth Drivers
1. Approval & Uptake of Oral Immunotherapy (OIT)
First-in-class therapies have provided the option of controlled desensitization, reducing risk of severe reactions.
2. Rapid R&D Growth in Allergy Immunotherapy
Pipeline includes OIT, EPIT patches, SLIT drops, DNA vaccines, and tolerance-inducing biologics.
3. Rising Incidence of Food Allergies in Children
Urbanization, altered microbiome exposure, and genetic predisposition drive prevalence.
4. High Unmet Need for Safe, Long-Term Desensitization
Families seek therapies that provide real-world protection against accidental exposure.
5. Increased Epinephrine Auto-Injector Use
Supports emergency preparedness for moderate-to-severe peanut allergy.

Market Restraints
• Risk of adverse reactions during OIT
• Need for long-term adherence to maintenance dosing
• High treatment cost for innovative therapies
• Limited data on lifelong immune tolerance after therapy
• Anxiety and compliance challenges in pediatric patient populations

Market Opportunities
1. Epicutaneous Immunotherapy (EPIT) Patches
Non-invasive, safer options for young children under development.
2. Biologic Therapies Targeting IgE Pathways
Monoclonal antibodies (e.g., anti-IgE) show strong potential in combination with OIT.
3. Microbiome-Based & DNA Vaccines
Emerging approaches to reprogram immune tolerance.
4. AI-Based Prediction of Anaphylaxis Risk
Personalized treatment plans based on immune profiling.
5. Expansion of Early Allergen Introduction Programs
Supports preventive strategies and early sensitization management.

Segmentation Overview
By Treatment Type
• Oral Immunotherapy (OIT)
• Epicutaneous Immunotherapy (EPIT)
• Sublingual Immunotherapy (SLIT)
• Biologic therapies
• Emergency epinephrine
• Supportive & avoidance-based management

By Age Group
• Pediatric (4-17 years)
• Adult

By Route of Administration
• Oral
• Transdermal
• Sublingual
• Injectable

By End User
• Allergy clinics
• Hospitals
• Ambulatory care centers
• Home-based therapy (post-initiation)

Explore Full Report here: https://exactitudeconsultancy.com/reports/71354/peanut-allergy-market

Regional Insights
North America - Largest Market
High food allergy prevalence, strong regulatory approvals for OIT, and robust research ecosystem.
Europe - Strong Growth in Immunotherapy Adoption
EPIT and SLIT clinical development accelerating in EU countries.
Asia Pacific - Fastest Growing
Rising awareness, urbanization-associated allergy prevalence, and expanding pediatric allergy care.
Latin America - Increasing Diagnosis Rates
Improved clinical access and emergency care.
Middle East & Africa - Emerging Adoption
Growing burden of pediatric food allergies and improved allergology services.

Competitive Landscape
Key players shaping the Peanut Allergy Market include:
• Aimmune Therapeutics (Nestlé Health Science)
• DBV Technologies
• AllerGenis
• Regeneron Pharmaceuticals
• Sanofi
• Novartis
• Genentech
• Aravax
• Prota Therapeutics
• ALK-Abelló
Focus areas: OIT commercialization, EPIT patch development, IgE-targeting biologics, and immune tolerance therapies.

Recent Market Developments
• Expanded commercialization efforts for FDA-approved OIT products
• Phase III advancements of EPIT patches for young children
• Increasing use of anti-IgE biologics alongside desensitization
• Growth in real-world data supporting long-term effectiveness of OIT
• AI-driven food allergy diagnostic tools becoming mainstream

Future Outlook (2025-2034)
The Peanut Allergy Market is expected to grow rapidly as:
• First- and second-generation OIT therapies expand globally
• EPIT patches reach regulatory approval for younger age groups
• Biologic therapies redefine severe allergy management
• Digital monitoring tools improve adherence and safety
• Predictive immunology supports personalized dosing strategies
By 2034, the market is forecasted to reach USD 4.08 billion, reflecting sustained demand for desensitization therapies and rising global allergy burden.
This report is also available in the following languages : Japanese (ピーナッツアレルギー市場), Korean (땅콩 알레르기 시장), Chinese (花生过敏市场), French (Marché des allergies aux arachides), German (Erdnussallergie-Markt), and Italian (Mercato delle allergie alle arachidi), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71354

Our More Reports:

Drug Eruptions Market
https://exactitudeconsultancy.com/reports/71408/drug-eruptions-market

Allergic Asthma due to Dermatophagoides Farinae Market
https://exactitudeconsultancy.com/reports/71484/allergic-asthma-due-to-dermatophagoides-farinae-market

DNA Vaccine Market
https://exactitudeconsultancy.com/reports/72393/dna-vaccine-market

Nasal Drug Delivery Market
https://exactitudeconsultancy.com/reports/72644/nasal-drug-delivery-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.